Product News and Recalls

Certain Antihypertensive Drugs May Correlate with Breast Cancer Risk

A story by Med Page Today highlights a recent study conducted by the Fred Hutchinson Cancer Research Center in Seattle. The study found a possible association between extended use of calcium-channel blockers and breast cancer.

Calcium-channel blockers are a commonly prescribed medication for high blood pressure. Examples of these include Cardizem and Norvasc along with many others. In postmenopausal women, the risk of breast cancer doubled for those who have been taking this ...

continue reading...

CR Bard to Buy Rochester Medical for $262 Million

According to Reuters, CR Bard Inc., a New Jersey-based medical device company, has announced that it will buy Rochester Medical Inc. for $262 million to gain market share in the urology homecare market.

Reuters states that Bard will pay $20 per share, or 45 percent more than the recent stock price.

Bard is currently defending ongoing lawsuits involving its IVC filter. There have been reports of a 25 percent failure rate involving a small group of patients ...

continue reading...

Another legal decision against Ethicon

A judge recently ordered Johnson & Johnson’s Ethicon division to pay Irish health care products manufacturer Covidien $176.5 million in damages over a patent dispute, Bloomberg reports.

At the conclusion of a non-jury trial, U.S. District Judge Janet Bond Arterton in New Haven, Conn., ruled that Ethicon infringed three U.S. patents for ultrasonic surgical instruments owned by Covidien.

Ethicon recently suffered another multi-million setback, in the form of an $11.1 million jury ...

continue reading...

Multidistrict Litigation Established to Handle Rising Number of Byetta/Januvia Cases

Anti-diabetic medications such as Byetta and Januvia are taken by thousands of people across the country to help manage their diabetes. Recent reports and studies have linked these drugs to dangerous side effects that the manufacturers have failed to disclose to the public. As a result numerous lawsuits have been filed across the country for injuries associated with the use of these drugs.

As a result of the increasing number of cases, the United States Judicial Panel on Multidistrict Litigation ...

continue reading...

Class I Recall on Stryker Spine Device

The Food and Drug Administration has issued a Class 1 Recall on Stryker Spine – OASYS Midline Occiput Plates due to reports of fracture of the pin that connects the implant’s tulip head to the plate body. This may cause serious adverse health consequences including blood loss, nerve injury, and the need for revision surgery to replace the fractured implant.

According to a FDA release, the OASYS Midline Occiput Plate is part of the OASYS Occipito-Cervico-Thoracic System used ...

continue reading...

Public Still Waiting for FDA Report on Benicar

In June, 2010, the FDA announced that it would continue to review potential risks and safety concerns of the antihypertensive medication Benicar after studies revealed serious cardiovascular risks. Now, three years later, an article on DrugInjuryWatch.com questions when the findings will be available to patients and doctors.

Two clinical trials highlighted a significantly higher rate of cardiovascular-related death in patients taking Benicar with Type 2 diabetes. Manufactured by Daiichi Sankyo, Benicar is prescribed to diminish hypertension ...

continue reading...
Page 213 of 386 «...190200210211212213214215...»